BB Biotech AG (XSWX:BION) Cash Payments: CHF-1,862.4 Mil (TTM As of Mar. 2026)


XSWX:BION BB Biotech AG XSWX:BION
32 GF Score
Price CHF50.60
! 4 Warning Signs
View Full Analysis

What is BB Biotech AG Cash Payments?

BB Biotech AG XSWX:BION -2.50% 32 Cash Payments is CHF-1,862.4 Mil as of Mar. 2026. GuruFocus rates XSWX:BION with a GF Score™ of 32/100. The stock has 4 warning signs investors should review.

BB Biotech AG's Cash Payments for the three months ended in Mar. 2026 was CHF-914.4 Mil.

BB Biotech AG's Cash Payments for the trailing twelve months (TTM) ended in Mar. 2026 was CHF-1,862.4 Mil.

BB Biotech AG Cash Payments Historical Data

* Premium members only.

The historical data trend for BB Biotech AG's Cash Payments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BB Biotech AG Cash Payments Chart

BB Biotech AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Payments
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,021.78 -245.06 -231.10 -258.45 -1,050.16

BB Biotech AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Payments Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -102.19 -153.80 -176.03 -618.15 -914.37
XSWX:BION
32GF Score
BB Biotech AG XSWX:BION
Cash Payments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BB Biotech AG Cash Payments Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Cash Payments represents cash flow paid from operating activities in the direct cash flow method.

GuruFocus lists following items in "Cash Payments" section for banks:
Cash Payments for Deposits by Banks and Customers
Cash Payments for Loans
Interest and Commission Paid
All Taxes Paid
Payments on Behalf of Employees
Other Cash Payments from Operating Activities

Cash Payments for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-1,862.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash Payments →
What does a Cash Payments of CHF-1,862.4 Mil mean?
BB Biotech AG (XSWX:BION) has a Cash Payments of CHF-1,862.4 Mil as of Mar. 2026. Cash Payments represents cash paid from operating activities in direct cash flow method. View historical data for BB Biotech AG and its competitors.
Is BB Biotech AG's Cash Payments too high?
BB Biotech AG's current Cash Payments is CHF-1,862.4 Mil. Overall, BB Biotech AG has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does BB Biotech AG's Cash Payments compare to VRTX and REGN?
BB Biotech AG's Cash Payments of CHF-1,862.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Payments for a Biotechnology company?
A good Cash Payments depends on the Biotechnology industry context. However, Cash Payments should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Payments mean?
A high Cash Payments can signal that a stock is expensive relative to its fundamentals. Cash Payments represents cash paid from operating activities in direct cash flow method. View historical data for BB Biotech AG and its competitors. BB Biotech AG's current Cash Payments is CHF-1,862.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BB Biotech AG stock overvalued right now?
BB Biotech AG (XSWX:BION) has a current Cash Payments of CHF-1,862.4 Mil. The current Cash Payments is CHF-1,862.4 Mil. BB Biotech AG's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Payments calculated?
Cash Payments is calculated from a company's financial statements. For BB Biotech AG (XSWX:BION), the current Cash Payments is CHF-1,862.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BB Biotech AG Business Description

Address Schwertstrasse 6, Schaffhausen, CHE, CH-8200
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market, and is one of the investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. Geographically company operates in the USA, Netherlands, Singapore, Great Britain, Canada, Switzerland, Curacao, and British Virgin Island.
32GF Score

Get the complete analysis for XSWX:BION

Cash Payments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF50.60
Price